ABEO
Income statement / Annual
Last year (2024), Abeona Therapeutics Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Abeona Therapeutics Inc.'s net income was -$63.73 M.
See Abeona Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$3.50 M |
$1.41 M |
$3.00 M |
$10.00 M |
$0.00 |
$3.00 M |
$837.00 K |
$889.00 K |
$1.04 M |
| Cost of Revenue |
$2.91 M
|
$1.61 M
|
$450.00 K
|
$4.46 M
|
$30.14 M
|
$8.68 M
|
$38.70 M
|
$16.99 M
|
$10.66 M
|
$0.00
|
| Gross Profit |
-$2.91 M
|
$1.90 M
|
$964.00 K
|
-$1.46 M
|
-$20.14 M
|
-$8.68 M
|
-$35.70 M
|
-$16.15 M
|
-$9.77 M
|
$1.04 M
|
| Gross Profit Ratio |
0
|
0.54
|
0.68
|
-0.49
|
-2.01
|
0
|
-11.91
|
-19.3
|
-10.99
|
1
|
| Research and Development Expenses |
$34.36 M
|
$31.09 M
|
$30.35 M
|
$34.33 M
|
$30.14 M
|
$48.57 M
|
$38.70 M
|
$16.99 M
|
$10.66 M
|
$4.72 M
|
| General & Administrative Expenses |
$29.85 M
|
$19.00 M
|
$17.26 M
|
$22.80 M
|
$23.78 M
|
$20.71 M
|
$20.11 M
|
$10.94 M
|
$13.29 M
|
$14.32 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$219.00 K
|
| Selling, General & Administrative Expenses |
$26.94 M
|
$19.00 M
|
$17.26 M
|
$22.80 M
|
$23.78 M
|
$20.71 M
|
$20.11 M
|
$10.94 M
|
$13.29 M
|
$14.32 M
|
| Other Expenses |
$0.00
|
-$1.07 M
|
$5.66 M
|
$3.25 M
|
$37.50 M
|
$7.82 M
|
$2.36 M
|
$741.00 K
|
$825.00 K
|
$551.00 K
|
| Operating Expenses |
$64.21 M
|
$49.03 M
|
$51.88 M
|
$60.37 M
|
$58.50 M
|
$69.27 M
|
$22.47 M
|
$11.68 M
|
$14.12 M
|
$19.59 M
|
| Cost And Expenses |
$0.00
|
$50.64 M
|
$46.67 M
|
$92.84 M
|
$91.42 M
|
$77.09 M
|
$61.16 M
|
$28.67 M
|
$24.77 M
|
$19.59 M
|
| Interest Income |
$4.25 M
|
$2.12 M
|
$431.00 K
|
$40.00 K
|
$1.30 M
|
$1.21 M
|
$1.51 M
|
$525.00 K
|
$2.01 M
|
$4.03 M
|
| Interest Expense |
$4.21 M
|
$418.00 K
|
$736.00 K
|
$3.67 M
|
$4.12 M
|
$400.00 K
|
$11.00 K
|
$8.00 K
|
$6.00 K
|
$6.00 K
|
| Depreciation & Amortization |
$2.91 M
|
$3.20 M
|
$4.58 M
|
$4.46 M
|
$5.60 M
|
$8.68 M
|
$2.36 M
|
$741.00 K
|
$825.00 K
|
$551.00 K
|
| EBITDA |
-$64.21 M |
-$50.57 M |
-$34.38 M |
-$76.80 M |
-$74.52 M |
-$67.61 M |
-$54.31 M |
-$26.58 M |
-$21.05 M |
-$13.97 M |
| EBITDA Ratio |
0
|
-14.45
|
-24.32
|
-25.6
|
-7.45
|
0
|
-18.12
|
-31.75
|
-23.68
|
-13.43
|
| Operating Income Ratio |
0
|
-13.47
|
-32.01
|
-29.95
|
-8.14
|
0
|
-19.4
|
-33.26
|
-26.86
|
-17.83
|
| Total Other Income/Expenses Net |
$477.00 K
|
-$7.05 M
|
$11.22 M
|
$4.90 M
|
-$2.81 M
|
$808.00 K
|
$1.50 M
|
$517.00 K
|
$2.01 M
|
$4.02 M
|
| Income Before Tax |
-$63.73 M
|
-$54.19 M
|
-$43.48 M
|
-$84.94 M
|
-$84.23 M
|
-$76.28 M
|
-$56.67 M
|
-$27.32 M
|
-$21.87 M
|
-$14.53 M
|
| Income Before Tax Ratio |
0
|
-15.48
|
-30.75
|
-28.31
|
-8.42
|
0
|
-18.9
|
-32.64
|
-24.6
|
-13.97
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$7.89 M
|
$3.67 M
|
$4.12 M
|
$400.00 K
|
$1.51 M
|
$525.00 K
|
$2.01 M
|
$4.03 M
|
| Net Income |
-$63.73 M
|
-$54.19 M
|
-$31.81 M
|
-$84.94 M
|
-$84.23 M
|
-$76.28 M
|
-$56.67 M
|
-$27.32 M
|
-$21.87 M
|
-$14.53 M
|
| Net Income Ratio |
0
|
-15.48
|
-22.5
|
-28.31
|
-8.42
|
0
|
-18.9
|
-32.64
|
-24.6
|
-13.97
|
| EPS |
-1.55 |
-2.53 |
-4.05 |
-21.5 |
-22.75 |
-38.07 |
-29.81 |
-16.4 |
-16 |
-13.16 |
| EPS Diluted |
-1.55 |
-2.53 |
-4.05 |
-21.5 |
-22.75 |
-38.07 |
-29.81 |
-16.4 |
-16 |
-13.16 |
| Weighted Average Shares Out |
$41.05 M
|
$21.38 M
|
$7.86 M
|
$3.94 M
|
$3.71 M
|
$2.01 M
|
$1.90 M
|
$1.67 M
|
$1.37 M
|
$1.10 M
|
| Weighted Average Shares Out Diluted |
$41.05 M
|
$21.38 M
|
$7.86 M
|
$3.94 M
|
$3.71 M
|
$2.01 M
|
$1.90 M
|
$1.67 M
|
$1.37 M
|
$1.10 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
